Compare DAC & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAC | ARDX |
|---|---|---|
| Founded | 1972 | 2007 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 2006 | 2014 |
| Metric | DAC | ARDX |
|---|---|---|
| Price | $107.03 | $5.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $105.00 | $15.14 |
| AVG Volume (30 Days) | 80.7K | ★ 3.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 3.30% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,607,000.00 |
| Revenue This Year | N/A | $38.22 |
| Revenue Next Year | N/A | $33.85 |
| P/E Ratio | $4.01 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $65.40 | $3.50 |
| 52 Week High | $118.83 | $8.40 |
| Indicator | DAC | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 44.12 | 36.90 |
| Support Level | $91.64 | $5.49 |
| Resistance Level | $118.83 | $6.23 |
| Average True Range (ATR) | 3.63 | 0.31 |
| MACD | -1.04 | -0.06 |
| Stochastic Oscillator | 4.78 | 13.56 |
Danaos Corp is an international owner of containerships. It provides international seaborne transportation services by operating vessels in the containership sector of the shipping industry. The company's customers include, HMM, MSC, Yang Ming, Hapag Lloyd, ZIM, Maersk, COSCO, OOCL, ONE, PIL, Sealead, Niledutch, Samudera, OSC, and Arkas. Geographically, the company operates in Australia-Asia, Europe, and America, with maximum revenue from the Australia-Asia region. It has two reporting segments Container vessels and Drybulk vessels segment. It generates the majority of its revenue from Container vessels.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.